Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A third of patients taking neoadjuvant Opdivo for inoperable advanced liver cancer had complete responses in an early analysis.
Atezolizumab plus chemotherapy delays disease progression in people with metastatic triple-negative breast cancer.
Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.
A high-fiber diet may help checkpoint medications work better—but probiotic supplements could interfere with response.
Lung cancer advocate Don Stranathan takes on the No. 1 cancer killer.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
Seventy percent of liver cancer patients had either a partial response or stable disease.
Checkpoint inhibitor alone or in combination shows benefits for different types of colorectal cancer.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Keytruda improved survival in people with favorable tumor biomarkers.
Checkpoint inhibitor immunotherapy, alone or in combination with chemotherapy, shows promise for advanced non-small-cell lung cancer.
Tecentriq combo slows progression of hard-to-treat breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.